NIAID says its Ebola therapy is safe

The National Institute of Allergy and Infectious Diseases Vaccine Research Center said IV infusions of its Ebola therapy mAb114 were well tolerated in the open-label, U.S. Phase I VRC 608 trial in 18 healthy adults. Data for the mAb that targets the receptor-binding domain of Ebola virus glycoprotein were published Thursday in The Lancet.

The study's authors also noted several advantages for using mAb114 in an Ebola outbreak setting, including the mAb's short infusion time and its formulation as a freeze-dried powder that does not require freezer storage...